Sensus Healthcare (SRTS) Cut to “Market Perform” at Northland Securities
Northland Securities lowered shares of Sensus Healthcare (NASDAQ:SRTS) from an outperform rating to a market perform rating in a research note published on Monday, The Fly reports.
SRTS has been the subject of a number of other research reports. Roth Capital initiated coverage on shares of Sensus Healthcare in a report on Wednesday, August 1st. They issued a buy rating and a $12.50 price objective for the company. B. Riley initiated coverage on shares of Sensus Healthcare in a research note on Wednesday, September 26th. They set a buy rating and a $12.50 target price for the company. initiated coverage on shares of Sensus Healthcare in a research note on Friday, July 6th. They set a buy rating and a $12.25 target price for the company. HC Wainwright initiated coverage on shares of Sensus Healthcare in a research note on Monday, August 27th. They set a buy rating and a $14.00 target price for the company. Finally, Maxim Group boosted their target price on shares of Sensus Healthcare from $9.00 to $10.00 and gave the stock a buy rating in a research note on Wednesday, September 19th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Sensus Healthcare has a consensus rating of Buy and an average target price of $12.25.
SRTS opened at $6.56 on Monday. Sensus Healthcare has a fifty-two week low of $4.91 and a fifty-two week high of $8.88. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.80 and a quick ratio of 3.49. The firm has a market capitalization of $134.80 million, a price-to-earnings ratio of -24.04 and a beta of -1.29.
In other news, insider Joseph C. Sardano sold 6,170 shares of the business’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $7.50, for a total transaction of $46,275.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 12,854 shares of company stock valued at $96,567 in the last three months. Corporate insiders own 41.10% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY purchased a new stake in shares of Sensus Healthcare during the second quarter worth about $152,000. BlackRock Inc. purchased a new stake in shares of Sensus Healthcare during the second quarter worth about $164,000. Commonwealth Equity Services LLC purchased a new stake in shares of Sensus Healthcare during the first quarter worth about $140,000. Renaissance Technologies LLC increased its stake in shares of Sensus Healthcare by 141.1% during the second quarter. Renaissance Technologies LLC now owns 27,488 shares of the company’s stock worth $200,000 after purchasing an additional 16,088 shares in the last quarter. Finally, Perkins Capital Management Inc. purchased a new stake in shares of Sensus Healthcare during the second quarter worth about $1,792,000. 7.25% of the stock is owned by institutional investors and hedge funds.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Article: How Buying a Call Option Works
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.